The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Immunotoxin Treatment of Cancer
Abstract
Immunotoxins are proteins used to treat cancer that are composed of an antibody fragment linked to a toxin. The immunotoxin binds to a surface antigen on a cancer cell, enters the cell by endocytosis, and kills it. The most potent immunotoxins are made from bacterial and plant toxins. Refinements over many years have produced recombinant immunotoxins; these therapeutic proteins are made using protein engineering. Individual immunotoxins are designed to treat specific cancers. To date, most success has been achieved treating hematologic tumors. Obstacles to successful treatment of solid tumors include poor penetration into tumor masses and the immune response to the toxin component of the immunotoxin, which limits the number of cycles that can be given. Strategies to overcome these limitations are being pursued.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robb, R. J., Greene, W. C., & Rusk, C. M. (1984) · The Journal of experimental medicine · doi:10.1084/jem.160.4.1126 · Cited by 725
Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., Jegasothy, B., Wood, G., Gordon, M., Heald, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.376 · Cited by 609
Hassan, R., Bera, T., & Pastan, I. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0801 · Cited by 441
Self-citationKreitman, R. J., Wilson, W. H., White, J. D., Stetler-Stevenson, M., Jaffe, E. S., Giardina, S., Waldmann, T. A., & Pastan, I. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1622 · Cited by 420
Self-citationA recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin
Chaudhary, V. K., Queen, G., Junghans, R. P., Waldmann, T. A., FitzGerald, D. J., & Pastan, I. (1989) · Nature · doi:10.1038/339394a0 · Cited by 413
Self-citationDelivery of Molecular Medicine to Solid Tumors
Jain, R. K. (1996) · Science · doi:10.1126/science.271.5252.1079 · Cited by 312
Improving antibody affinity by mimicking somatic hypermutation in vitro
Chowdhury, P. S., & Pastan, I. (1999) · Nature Biotechnology · doi:10.1038/9872 · Cited by 256
Self-citationAmlot, P., Stone, M., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., & Ghetie, V (1993) · Blood · doi:10.1182/blood.v82.9.2624.2624 · Cited by 235
Bacha, P., Williams, D. P., Waters, C., Williams, J. M., Murphy, J. R., & Strom, T. B. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.2.612 · Cited by 220
Brinkmann, U., Pai, L. H., FitzGerald, D. J., Willingham, M. C., & Pastan, I. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8616 · Cited by 214
Self-citation
Cited by
Therapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Getting Across the Cell Membrane: An Overview for Small Molecules, Peptides, and Proteins
Yang, N. J., & Hinner, M. J. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2272-7_3 · Cited by 826
Mechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
Prodrug Strategies in Anticancer Chemotherapy
Kratz, F., Müller, I. A., Ryppa, C., & Warnecke, A. (2008) · ChemMedChem · doi:10.1002/cmdc.200700159 · Cited by 486
Dual targeting strategies with bispecific antibodies
Kontermann, R. (2012) · mAbs · doi:10.4161/mabs.4.2.19000 · Cited by 435
Metadata
- Authors
- Pastan, I., Hassan, R., FitzGerald, D. J., & Kreitman, R. J.
- Venue
- Annual Review of Medicine
- Publisher
- Annual Reviews
- Published
- 2007-02-01
- Volume
- 58
- Issue
- 1
- Pages
- 221-237
- ISSN
- 0066-4219 (ISSN-L)
- 1545-326X
- OpenAlex
- W2106443011
- Cited by
- 359
- References
- 52
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunotoxin Treatment of Cancer. https://app.cochat.ai/papers/10.1146/annurev.med.58.070605.115320
- The paper
- Pastan, I., Hassan, R., FitzGerald, D. J., & Kreitman, R. J. (2007). Immunotoxin Treatment of Cancer. Annual Review of Medicine. https://doi.org/10.1146/annurev.med.58.070605.115320
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.